Two endoplasmic reticulum-associated degradation (ERAD) systems for the novel variant of the mutant dysferlin: ubiquitin/proteasome ERAD(I) and autophagy/lysosome ERAD(II).

Overview of attention for article published in Human Molecular Genetics, March 2007

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (84th percentile)
High Attention Score compared to outputs of the same age and source (80th percentile)

Mentioned by

patent: 3 patents

Citations

dimensions_citation: 290 Dimensions

Readers on

mendeley: 181 Mendeley

Summary Patents Dimensions citations

So far, Altmetric has seen 3 patents that reference this research output.

Use of epigenome-modifying compounds for the treatment of genetic muscular diseases…

Grant US-9526742-B2

United States of America

Use of compounds modifying the epigenome for the treatment of diseases genetic muscle…

Application FR-2993461-A1

France

USE OF EPIGENOME-MODIFYING COMPOUNDS FOR THE TREATMENT OF GENETIC MUSCULAR DISEASES…

Application WO-2014013184-A1

World Intellectual Property Organisation (WIPO)

This page shows the most recent patents that mention this research output.

Click here to find out how to access more activity.